Extracting the Benefit of Nexrutine(®) for Cancer Prevention.

The current standard of care for prostate cancer includes hormone therapy, radiation therapy and radical prostatectomy, each with its own set of undesirable side effects. In this regard there is an unmet need to develop strategies that can prevent or delay the development of clinical prostate cancer.

One potential area involves the use of natural compounds involving botanicals. Along these lines we have found that Nexrutine(®), a dietary supplement derived from Phellodendron amurense bark extract, has prostate cancer prevention activity. The "extract" nature of this botanical, which constitutes a blend of several active protoberberine alkaloids, allows it to target several pathways deregulated in prostate cancer simultaneously. In this review, we will emphasize the prospective translational benefit of Nexrutine(®) as a chemopreventive agent for prostate cancer management. The potential of Nexrutine(®) was first identified and has subsequently been most exhaustively studied with reference to prostate cancer. Therefore the focus of this review is on the use of Nexrutine(®) in prostate cancer. In addition we have summarized the emerging evidence regarding the use of Nexrutine(®) in other tumor models to demonstrate the potential benefits of Nexrutine(®).

Current pharmacology reports. 2015 Mar 21 [Epub]

Suleman S Hussain, Darpan Patel, Rita Ghosh, Addanki P Kumar

Department of Urology, The University of Texas Health Science Center, San Antonio, TX ; Department of Pharmacology, The University of Texas Health Science Center, San Antonio, TX. , Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX ; School of Medicine, Health Rest & Care System Management, School of Nursing, The University of Texas Health Science Center, San Antonio, TX. , Department of Urology, The University of Texas Health Science Center, San Antonio, TX ; Department of Pharmacology, The University of Texas Health Science Center, San Antonio, TX ; Department of Molecular Medicine, The University of Texas Health Science Center, San Antonio, TX ; Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX. , Department of Urology, The University of Texas Health Science Center, San Antonio, TX ; Department of Pharmacology, The University of Texas Health Science Center, San Antonio, TX ; Department of Molecular Medicine, The University of Texas Health Science Center, San Antonio, TX ; Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX ; South Texas Veterans Health Care System, San Antonio, TX.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe